Biotech

The Global Clinical Trials Connect 2023 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research. This multidisciplinary program involves broad participation of people from clinical trials community from around the globe who are focused on learning more about clinical research, clinical trials planning and management.

Hundreds of clinical trials using AAV are underway, with several hundred more in preclinical development. Given the sheer volume of studies in the pipeline, the need to administer high doses, the clinical holds placed on gene therapy trials, and regulatory bodies being increasingly stringent on the safety standards they require; it has never been more important to create and implement an AAV safety strategy that’s fit for purpose! In this setting, the inaugural Optimizing AAV Safety Summit is bringing together key leaders focussed specifically on solving AAV safety challenges across toxicology, pharmacology, non-clinical study leads, clinical development safety specialists and bioanalysis innovators to gain insights on optimizing AAV safety processes and benefit-risk analysis to shorten timelines and prevent potential delays.Join us in Boston alongside key biotech and pharma leaders from the likes of Spark Therapeutics, Ask Bio, Eli Lilly, Takeda, and more in the AAV space who are prioritizing the development of safe and effective genetic therapies, learn how clinical safety signals have changed how companies are approaching their pipeline progression, and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development.

The 2nd Annual Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely. Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach. Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.

The two-day conference and one-day exhibition provides the perfect venue for easy, informal discussions for manufacturing, packaging, laboratory services and more!

The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress. The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.

The CNS Summit has become the premiere event for all those involved in clinical development to meet, network, and participate in initiatives that will shape the future. The summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. The mission is to have a positive impact on the success of clinical development programs. Join the pharma and biotech R&D leaders, the top tech companies involved in clinical development and healthcare innovation, investigator sites, service companies, and the regulators from FDA and EMA.

“The Macrophage-directed Therapies Summit is returning for the 4th year, back to Boston – and continues to be the leading industry-focused forum uniting this emerging community of over 100 leaders to review cutting-edge advances in the discovery, preclinical, translational, and clinical development of macrophage-directed therapies.Covering discovery to the clinic and a brand-new Biomarkers Bootcamp, the summit is returning with two tracks of content.Join the likes of Gilead Sciences, Pionyr Immunotherapeutics, KAHR Medical, Codiak BioSciences, Ichnos Sciences, and Enlivex Therapeutics Ltd, and receive the latest updates on clinical progress, novel approaches, and targets to broaden the spectrum of macrophage targeting. With continuing growth in the macrophage space, delve into:
CD47 targeting and other ‘don’t eat me’ signals
Safety concerns due to model translatability and dosing
Optimal combination or monotherapy discovery
Learn from our expert speaker faculty, who will be sharing more exclusive new or unpublished insights than ever before.”

Connect with top-notch industry speakers delivering impactful presentations with practical solutions and best practices to take you to the next level in leading and managing the business aspects of clinical trials. It’s a place where clinical research professionals can connect on the latest topics, trends and technologies for streamlining the business aspects of clinical trials. Areas covered are clinical trial outsourcing and vendor management, contracting and budgeting, financial management, business operations and accelerating clinical study start-up.

Capture the unmatched potential of these versatile stem cells in regenerative medicine and cell therapy by advancing scale-up, differentiation and quality to reduce variability and ensure stable and robust cell lines. Gain valuable insights from industry experts, through exclusive talks and discussions, into approaches to transform your manufacturing processes by exploring technology innovations, leveraging automation and AI, evolving analytics and advancing cryopreservation.

Connect with iPSC trailblazers, including Century Therapeutics, Sana Biotechnology and Novo Nordisk, to create best-in-class iPSC-derived cell therapies for immuno-oncology and regenerative medicine.